These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 9783530

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Bioavailability of rifampicin, isoniazid and pyrazinamide in a triple drug formulation: comparison of plasma and urine kinetics.
    Gurumurthy P, Ramachandran G, Vijayalakshmi S, Kumar AK, Venkatesan P, Chandrasekaran V, Vjayasekaran V, Kumaraswami V, Prabhakar R.
    Int J Tuberc Lung Dis; 1999 Feb; 3(2):119-25. PubMed ID: 10091876
    [Abstract] [Full Text] [Related]

  • 4. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
    Agrawal S, Singh I, Kaur KJ, Bhade SR, Kaul CL, Panchagnula R.
    Int J Pharm; 2004 May 19; 276(1-2):41-9. PubMed ID: 15113612
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. I. Single-dose study.
    Acocella G, Nonis A, Gialdroni-Grassi G, Grassi C.
    Am Rev Respir Dis; 1988 Oct 19; 138(4):882-5. PubMed ID: 3202464
    [Abstract] [Full Text] [Related]

  • 8. Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations.
    Agrawal S, Singh I, Kaur KJ, Bhade SR, Kaul CL, Panchagnula R.
    Int J Clin Pharmacol Ther; 2002 Oct 19; 40(10):474-81. PubMed ID: 12395981
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparative bioequivalence study of rifampicin and isoniazid combinations in healthy volunteers.
    Padgaonkar KA, Revankar SN, Bhatt AD, Vaz JA, Desai ND, D'Sa S, Shah V, Gandewar K.
    Int J Tuberc Lung Dis; 1999 Jul 19; 3(7):627-31. PubMed ID: 10423226
    [Abstract] [Full Text] [Related]

  • 11. Relative bioavailability of rifampicin, isoniazid and ethambutol from a combination tablet vs. concomitant administration of a capsule containing rifampicin and a tablet containing isoniazid and ethambutol.
    Schall R, Müller FO, Duursema L, Groenewoud G, Hundt HK, Middle MV, Mogilnicka EM, Swart KJ.
    Arzneimittelforschung; 1995 Nov 19; 45(11):1236-9. PubMed ID: 8929247
    [Abstract] [Full Text] [Related]

  • 12. Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. II. Two-month, daily administration study.
    Acocella G, Nonis A, Perna G, Patane E, Gialdroni-Grassi G, Grassi C.
    Am Rev Respir Dis; 1988 Oct 19; 138(4):886-90. PubMed ID: 3202465
    [Abstract] [Full Text] [Related]

  • 13. Bioavailability of isoniazid, rifampicin and pyrazinamide (in free combination or fixed-triple formulation) in intermittent antituberculous chemotherapy.
    Acocella G, Luisetti M, Grassi GG, Peona V, Pozzi E, Grassi C.
    Monaldi Arch Chest Dis; 1993 Oct 19; 48(3):205-9. PubMed ID: 8369784
    [Abstract] [Full Text] [Related]

  • 14. Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market.
    Pillai G, Fourie PB, Padayatchi N, Onyebujoh PC, McIlleron H, Smith PJ, Gabriels G.
    Int J Tuberc Lung Dis; 1999 Nov 19; 3(11 Suppl 3):S309-16; discussion S317-21. PubMed ID: 10593710
    [Abstract] [Full Text] [Related]

  • 15. Bioequivalence study of rifampicin in fixed-dose combination of rifampicin and isoniazid vs. separate formulations.
    Panchagnula R, Singh I, Kaur KJ, Kaul CL.
    Methods Find Exp Clin Pharmacol; 1999 Nov 19; 21(9):625-8. PubMed ID: 10669909
    [Abstract] [Full Text] [Related]

  • 16. Pharmaceutical formulation of a fixed-dose anti-tuberculosis combination.
    Danckwerts MP, Ebrahim S, Pillay V.
    Int J Tuberc Lung Dis; 2003 Mar 19; 7(3):289-97. PubMed ID: 12661846
    [Abstract] [Full Text] [Related]

  • 17. Elevated gatifloxacin and reduced rifampicin concentrations in a single-dose interaction study amongst healthy volunteers.
    McIlleron H, Norman J, Kanyok TP, Fourie PB, Horton J, Smith PJ.
    J Antimicrob Chemother; 2007 Dec 19; 60(6):1398-401. PubMed ID: 17951604
    [Abstract] [Full Text] [Related]

  • 18. Relative bioavailability of rifampicin in a three-drug fixed-dose combination formulation.
    Milán-Segovia RC, Domínguez-Ramírez AM, Jung-Cook H, Magaña-Aquino M, Romero-Méndez MC, Medellín-Garibay SE, Vigna-Pérez M, Romano-Moreno S.
    Int J Tuberc Lung Dis; 2010 Nov 19; 14(11):1454-60. PubMed ID: 20937187
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics of isoniazid in pulmonary tuberculosis--a comparative study at two dose levels.
    Roy V, Tekur U, Chopra K.
    Indian Pediatr; 1996 Apr 19; 33(4):287-91. PubMed ID: 8772902
    [Abstract] [Full Text] [Related]

  • 20. Assessment of bioequivalence of rifampicin, isoniazid and pyrazinamide in a four drug fixed dose combination with separate formulations at the same dose levels.
    Agrawal S, Kaur KJ, Singh I, Bhade SR, Kaul CL, Panchagnula R.
    Int J Pharm; 2002 Feb 21; 233(1-2):169-77. PubMed ID: 11897421
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.